Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Claturafenib | Phase 1 | Phase 1 | 2 | 0 | 0 | 2 | 0 | — | — | Jul 5, 2022 |
| Pan-RAF/MEK Molecular Glue NST-628 | Phase 1 | Phase 1 | 2 | 1 | 0 | 2 | 0 | — | — | Apr 9, 2024 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | Phase 1 | Phase 1 | 1 | 0 | 0 | 3 | 0 | — | — | Jul 16, 2019 |
| Mobocertinib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 4, 2019 |
| Trichostatin A | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 27, 2018 |
| WRN Inhibitor HRO761 | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 27, 2023 |
| RG7112 | Phase 1 | Phase 1 | 0 | 0 | 0 | 6 | 0 | — | — | 2007-12 |
| MTOR Kinase Inhibitor AZD8055 | Phase 1 | Phase 1 | 0 | 0 | 0 | 5 | 0 | — | — | 2008-07 |
| 5-Fluoro-2-Deoxycytidine | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 1999-04 |
| Checkpoint Kinase Inhibitor AZD7762 | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-12 |
| Lifirafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 20, 2013 |
| Selitrectinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | Jul 3, 2017 |
| Agerafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-06 |
| ALK Inhibitor ASP3026 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-12 |
| Anti-HER3 Monoclonal Antibody GSK2849330 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 26, 2013 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 11, 2015 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-06 |
| HDM2 Inhibitor MK-8242 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 18, 2011 |
| JAK2 Inhibitor AZD1480 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-04 |
| Mcl-1 Inhibitor MIK665 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 12, 2017 |
| MET Tyrosine Kinase Inhibitor SGX523 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-01 |
| Pan-AKT Kinase Inhibitor GSK690693 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-04 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | May 26, 2016 |
| Anti-ErbB3 Monoclonal Antibody AV-203 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-05 |
| ARQ092 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-11 |
| AZD5438 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-07 |
| BRAF Inhibitor | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-04 |
| FGFR4 Inhibitor H3B-6527 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 28, 2016 |
| FGFR Inhibitor ASP5878 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 5, 2013 |
| Fisogatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 31, 2015 |
| FLT3 Inhibitor FF-10101 Succinate | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 5, 2017 |
| HDAC Inhibitor OBP-801 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-03 |
| MEK Inhibitor RO4987655 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-01 |
| Omipalisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 31, 2009 |
| Pan-RAF Inhibitor LY3009120 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 26, 2013 |
| PARP Inhibitor AZD2461 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-11 |
| PI3Kbeta Inhibitor AZD8186 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 24, 2018 |
| Rindopepimut | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-06 |
| Tizaterkib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 15, 2020 |
| Tozasertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-05 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.